KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Internal Medicine / 2026 / Volume: 3 Issue: Supplement 1 Special Issue

Osteosarcoma of rib treated with regorafenib: a case report

Orkun Sakar(Bursa Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı)0000-0002-1624-4339
Cemre Uçaryılmaz(KOÇ ÜNİVERSİTESİ)0000-0002-5758-1120
Ahmet Bilgehan Şahin(TIP FAKÜLTESİ)0000-0002-7846-0870
Türkkan Evrensel(TIP FAKÜLTESİ)0000-0002-9732-5340
Cengiz Gebitekin(TIP FAKÜLTESİ)0000-0001-8718-9499
Sayfa
—
Yayın Tarihi
2021-03-07
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here, we presented a rare case of osteosarcoma.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints.
📊
Temel Bulgular & Veri:Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints.
💡
Sonuç & Katkı:Here, we presented a rare case of osteosarcoma.
🔬Tür:Case Report
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:oncology · osteosarcoma of rib · regorafenib

Abstract

Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints. Here, we presented a rare case of osteosarcoma.

🔖

Bu Makaleye Atıf Yap

Sakar, O., Uçaryılmaz, C., Şahin, A. B., Evrensel, T., Gebitekin, C. (2021). Osteosarcoma of rib treated with regorafenib: a case report. Turkish Journal of Internal Medicine, Volume: 3 Issue: Supplement 1 Special Issue. https://doi.org/10.46310/tjim.875951

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
  2. Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
  3. Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.
  4. Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.